University of California San Francisco
Give to UCSF
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
Taking into account genetic factors that can change PSA levels not associated with cancer, the screening accuracy can be improved.
UCSF scientists have found that brain cancer glioblastoma can cause cognitive decline by affecting neural connections, but the epilepsy drug gabapentin shows promise in blocking this activity, offering hope for new treatments.
Transgender women keep their prostates even after gender-affirming surgery, and the estimated risk of prostate cancer is at about 14 cases per 10,000 people.
Leading cancer researchers from UCSF will present at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 14-19, 2023, in Orlando.
Thermo Fisher Scientific Inc. and UCSF will accelerate advanced cell therapies for difficult to treat conditions like cancer from a new manufacturing facility.
A clinical trial showed that, rather than removing lymph nodes, leaving them intact could help immunotherapy activate tumor-fighting T cells in the lymph nodes.
For the past 30 years, the California Tobacco Control Program has helped Californians save $816 billion in health care costs.
A new digital tool helps to calculate breast cancer risk for those who may develop advanced cancer that goes undiagnosed despite regular screenings.
Sick leave coverage expansion were associated with higher rates of mammography screening and colorectal screening, potentially leading to better health outcomes.
The WISDOM 2.0 study aims to transform breast cancer screening by using a personalized approach and will expand to women as young as 30.
Balyn Zaro’s lab investigates the cause and consequence of genetic diversity in the immune system, in hopes that her discoveries can lead to better treatments for all patients.
Trillions of invisible organisms make up the human microbiome. Now, medical scientists want to put these bugs to work.
Resecting brain tumors called gliomas as much as possible soon after diagnosis offers a distinct survival advantage when looking at the disease trajectory 10 years later, find UCSF researchers.
Researchers have discovered a cellular uptake pathway for larger molecules that delivers cell-permeable drugs efficiently.
Through decades of biobanking at UCSF, researchers were able to comprehensively map intra-cellular signaling in the cells of recurrent glioblastoma, identifying novel cell-extrinsic therapeutic targets.
T-cells can be directed to produce cytokine, a powerful anti-cancer component, when they encounter cancer cells. This holds tremendous promise for cancer immunotherapy.
UCSF experts in multiple myeloma and other hematologic malignancies will attend the American Society of Hematology’s (ASH) 64th Annual Meeting and Exposition.
A new sophisticated machine learning technique using a molecular library of commands guides engineered immune cells to seek out and tirelessly kill cancer cells.
UCSF breast cancer experts will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the largest and most prestigious breast cancer conference.
Researchers have identified specific immune cells that drive deadly heart inflammation in a small fraction of patients treated with powerful cancer immunotherapy drugs.
E-cigarettes and marijuana have similar harmful effects on the heart as tobacco cigarettes, opening the door to abnormal heart rhythms, reports a team of researchers at UCSF.
A new method of comparing massive numbers of CAR-T cells can determine which is most effective and long-lasting against cancer.
Bacteria in our guts may play a significant role in the metabolism of anti-cancer drugs that are critical for treating colon cancer and other types of cancers.
Immune checkpoint inhibitors (ICIs) used in cancer care can cause myocarditis, a potentially fatal side effect, and it appears that the adverse cardiac effects may disproportionally impact female patients.
A new therapy pulls forward a mutated version of the KRAS protein to help the immune system recognize and destroy cancer cells.
UCSF-led research outlines the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. Their findings could reveal the mechanism of neoplastic progression and provide targets for immunotherapy to inhibit progression or treat invasive disease.
